biologic

Bat

Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)

Loss of exclusivityMarch 2025projected — 12-year biologic exclusivity estimate
CompanyEmergent BioSolutions Canada Inc.

Drug detail

Brand nameBat
Active ingredientBotulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)
Strength>4500U
Dosage formSolution
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2013
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bat patent cliff — loss of exclusivity March 2025 | CliffBio